An Interview with Institute of Oncology Research, Dr. Francesco Bertoni, MD

"The HTG EdgeSeq technology represents a nice way to combine the possibility of working with FFPE specimens and next-generation approaches.  Moreover, the HTG EdgeSeq Oncology Biomarker Panel (OBP) can be applied on in vitro models and then the results can be validated on FFPE specimens from clinical studies using the same assay." Dr. Bertoni, MD

Read full interview here